SCHEMBL3464696

SCHEMBL3464696

CCCCn1c(SC2=COC(c3ccccc3I)O2)nc2c(=O)n(COCCOC)cnc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.34
KDM4E B2RXH2 7/20 0.34
HPGD P15428 4/20 0.34
GAA P10253 2/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 5/20 0.33
TSHR P16473 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HSP90AA1 P07900 4/20 0.32
HSP90AB1 P08238 4/20 0.32
USP2 O75604 2/20 0.31
PDE4A P27815 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA2B P29275 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
ERBB2 P04626 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3465017 0.91 KDM4E (0.32) ALDH1A1KDM4EHPGDGAAHTT
SCHEMBL3464950 0.77 HSP90AA1 (0.53) HSP90AA1HSP90AB1ADORA2AADORA2BERBB2
SCHEMBL3464692 0.75 HSP90AA1 (0.51) HSP90AA1HSP90AB1ERBB2
SCHEMBL3466047 0.74 HSP90AA1 (0.38) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL3465113 0.72 ERBB2 (0.60) ALDH1A1HSP90AA1HSP90AB1PDE4APDE4B
SCHEMBL3464629 0.70 TRAP1 (0.45) HSP90AA1HSP90AB1ERBB2
SCHEMBL3465438 0.70 TRAP1 (0.42) HSP90AA1HSP90AB1ERBB2
SCHEMBL3465014 0.69 TRAP1 (0.48) HSP90AA1HSP90AB1ERBB2
SCHEMBL15609506 0.69 HSP90AB1 (0.42) HSP90AA1HSP90AB1ERBB2
SCHEMBL3465502 0.68 HSP90B1 (0.43) HSP90AA1HSP90AB1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2010-09-23 US disclosed
EP-2183221-A1 NEW COMPOUNDS AS HSP90 INHIBITORS Crystax Pharmaceuticals S.L. (ES) 2010-05-12 EP disclosed
WO-2009007399-A1 NEW COMPOUNDS AS HSP90 INHIBITORS CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS HSP90AB1, HSP90AB2P, HSP90AA1 ALDH1A1 1875/4885KDM4E 3594/4885HPGD 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.